Table 3.

Treatment-related adverse events (≥ 10% or any toxicities with grade 3 or higher).

Cohort A (MSI-H)Cohort B (MSS)
n = 10n = 40
Adverse event, n (%)All gradesGrade ≥3All gradesGrade ≥3
All events10 (100)1 (10)40 (100)10 (25)
Diarrhea8 (80)0 (0)35 (87.5)2 (5.0)
Decreased appetite0 (0)0 (0)13 (32.5)3 (7.5)
Nausea4 (40)0 (0)11 (27.5)1 (2.5)
Vomiting1 (10)0 (0)7 (17.5)0 (0)
Fever4 (40)1 (10)6 (15.0)0 (0)
Malaise0 (0)0 (0)6 (15.0)0 (0)
Fatigue0 (0)0 (0)5 (12.5)0 (0)
Hypothyroidism2 (20)0 (0)5 (12.5)0 (0)
Rash2 (20)0 (0)3 (7.5)1 (2.5)
Abdominal pain2 (20)0 (0)2 (5.0)1 (2.5)
Anemia0 (0)0 (0)2 (5.0)1 (2.5)
Hypokalemia0 (0)0 (0)2 (5.0)1 (2.5)
Alanine aminotransferase increased0 (0)0 (0)2 (5.0)0 (0)
Infusion-related reaction1 (10)0 (0)1 (2.5)0 (0)
Hearing impaired0 (0)0 (0)1 (2.5)1 (2.5)
Colitis0 (0)0 (0)1 (2.5)1 (2.5)
Serum amylase increased0 (0)0 (0)1 (2.5)1 (2.5)
Alkaline phosphatase increased0 (0)0 (0)1 (2.5)1 (2.5)
Platelet count decreased1 (10)0 (0)0 (0)0 (0)
Cheilitis1 (10)0 (0)0 (0)0 (0)